{"version":"1.0","type":"link","title":"Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study.","author_name":"Zhao X 외","author_url":"https://prs-insight.online/author/Zhao%20X","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/96572","thumbnail_width":1200,"thumbnail_height":630}